p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53

被引:0
|
作者
Christine Wasylyk
Roberto Salvi
Manuela Argentini
Christine Dureuil
Isabelle Delumeau
Joseph Abecassis
Laurent Debussche
Bohdan Wasylyk
机构
[1] Institut de Génétique et de Biologie Moléculaire et Cellulaire,Département d'Oncologie
[2] CNRS/INSERM/ULP,undefined
[3] Centre de Recherche de Vitry-Alfortville,undefined
[4] Rhóne-Poulenc Rorer,undefined
[5] Laboratoire de Biologie Tumorale,undefined
来源
Oncogene | 1999年 / 18卷
关键词
p21; E2F; E6; cell cycle; apoptosis; antisense;
D O I
暂无
中图分类号
学科分类号
摘要
The p53 tumour suppressor is frequently inactivated in human tumours. One form of inactivation results from overexpression of MDM2, that normally forms a negative auto-regulatory loop with p53 and inhibits its activity through complex formation. We have investigated whether disrupting the MDM2-p53 complex in cells that overexpress MDM2 is sufficient to trigger p53 mediated cell death. We find that expression of a peptide homologue of p53 that binds to MDM2 leads to increased p53 levels and transcriptional activity. The consequences are increased expression of the downstream effectors MDM2 and p21WAF1/CIP1, inhibition of colony formation, cell cycle arrest and cell death. There is also a decrease in E2F activity, that might have been due to the known physical and functional interactions of MDM2 with E2F1/DP1. However, this decrease is p53 dependent, as are also colony formation, cell cycle arrest and cell death. These results show that a peptide homologue of p53 is sufficient to induce p53 dependent cell death in cells overexpressing MDM2, and support the notion that disruption of the p53-MDM2 complex is a target for the development of therapeutic agents.
引用
收藏
页码:1921 / 1934
页数:13
相关论文
共 50 条
  • [1] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Wasylyk, C
    Salvi, R
    Argentini, M
    Dureuil, C
    Delumeau, I
    Abecassis, J
    Debussche, L
    Wasylyk, B
    [J]. ONCOGENE, 1999, 18 (11) : 1921 - 1934
  • [2] Binding of an inhibitor of the p53/MDM2 interaction to MDM2
    Duncan, SJ
    Cooper, MA
    Williams, DH
    [J]. CHEMICAL COMMUNICATIONS, 2003, (03) : 316 - 317
  • [3] On the biosynthesis of an inhibitor of the p53/MDM2 interaction
    Duncan, SJ
    Williams, DH
    Ainsworth, M
    Martin, S
    Ford, R
    Wrigley, SK
    [J]. TETRAHEDRON LETTERS, 2002, 43 (06) : 1075 - 1078
  • [4] Nanoparticle mediated inhibition of the MDM2:p53 interaction
    Arvizo, Rochelle R.
    Fischer, Nicholas O.
    Jerry, D. Joseph
    Rotello, Vincent M.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233
  • [5] P53 Mdm2 Inhibitors
    Khoury, Kareem
    Doemling, Alex
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
  • [6] MDM2与p53
    金晶
    刘耕陶
    [J]. 癌症, 2001, (06) : 663 - 666
  • [7] MDM2 and BCL-2: to p53 or not to p53?
    Wang, Eunice S.
    [J]. BLOOD, 2023, 141 (11) : 1237 - 1238
  • [8] Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53
    Xirodimas, DP
    Stephen, CW
    Lane, DP
    [J]. EXPERIMENTAL CELL RESEARCH, 2001, 270 (01) : 66 - 77
  • [9] Inorganic arsenic induces MDM2, p53, and their phosphorylation and affects the MDM2/p53 complex in vitro
    Yin, Jinyao
    Zhou, Qian
    Tan, Jingwen
    Che, Wangjun
    He, Yuefeng
    [J]. ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (58) : 88078 - 88088
  • [10] P53 α-helix mimetics antagonize p53/MDM2 interaction and activate p53
    Chen, LH
    Yin, H
    Farooqi, B
    Sebti, S
    Hamilton, AD
    Chen, JD
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (06) : 1019 - 1025